臨床泌尿器科71巻1号

2017年01月発行

特集 免疫チェックポイント阻害薬って何?─基礎から理解するがん治療のトレンド

前立腺がんにおける免疫チェックポイント阻害薬の現況

著者： 小坂威雄¹ 大家基嗣¹

所属機関： ¹慶應義塾大学医学部泌尿器科教室

ページ範囲：P.58 - P.64

文献概要

▶ポイント

・ホルモン療法は免疫系の制御を介して，前立腺や前立腺がん組織に対する腫瘍免疫応答を調製する可能性が報告されている．

・免疫チェックポイント阻害薬の各種の臨床試験の結果からは，前立腺がんにおける腫瘍免疫を増強する戦略は，去勢抵抗性前立腺がんでも，特に病状が進行していない段階でより効果的である可能性が示唆されている．

・免疫チェックポイント阻害薬の抗腫瘍効果の増強を期待して，ホルモン療法や放射線療法などと併用する多くの臨床試験が計画・遂行中であり，今後の成果が期待される．

参考文献

1） Pardoll DM : The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 : 252─264, 2012

2） Mahoney KM, Rennert PD and Freeman GJ : Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14 : 561─584, 2015

3） Ebelt K, Babaryka G, Figel AM, et al : Dominance of CD4＋ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 68 : 1─10, 2008

4） Gannon PO, Poisson AO, Delvoye N, et al : Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 348 : 9─17, 2009

5） Hussein MR, Al-Assiri M and Musalam AO : Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol 86 : 108─113, 2009

6） Shirotake S, Miyajima A, Kosaka T, et al : Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. Am J Pathol 180 : 1008─1016, 2012

7） Davidsson S, Ohlson AL, Andersson SO, et al : CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3 （＋） regulatory T cells with respect to lethal prostate cancer. Mod Pathol 26 : 448─455, 2013

8） Ebelt K, Babaryka G, Frankenberger B, et al : Prostate cancer lesions are surrounded by FOXP3＋, PD-1＋ and B7-H1＋ lymphocyte clusters. Eur J Cancer 45 : 1664─1672, 2009

9） Kiniwa Y, Miyahara Y, Wang HY, et al : CD8＋ Foxp3＋ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13 : 6947─6958, 2007

10） Sutherland JS, Goldberg GL, Hammett MV, et al : Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 175 : 2741─2753, 2005

11） Wilson CA, Mrose SA and Thomas DW : Enhanced production of B lymphocytes after castration. Blood 85 : 1535─1539, 1995

12） Drake CG, Doody AD, Mihalyo MA, et al : Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7 : 239─249, 2005

13） Mercader M, Bodner BK, Moser MT, et al : T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 98 : 14565─14570, 2001

14） Demaria S, Ng B, Devitt ML, et al : Ionizing radiation inhibition of distant untreated tumors （abscopal effect） is immune mediated. Int J Radiat Oncol Biol Phys 58 : 862─870, 2004

15） Finkelstein SE, Salenius S, Mantz CA, et al : Combining immunotherapy and radiation for prostate cancer. Clin Genitourin Cancer 13 : 1─9, 2015

16） Sharabi AB, Lim M, DeWeese TL, et al : Radiation and checkpoint blockade immunotherapy : radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16 : e498─509, 2015

17） Slovin SF, Higano CS, Hamid O, et al : Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer : results from an open-label, multicenter phase I/II study. Ann Oncol 24 : 1813─1821, 2013

18） Kwon ED, Drake CG, Scher HI, et al : Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy （CA184-043） : a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15 : 700─712, 2014

19） Killock D : Prostate cancer : mixed responses to ipilimumab. Nat Rev Urol 11 : 305, 2014

20） Parker C : A near miss for prostate cancer immunotherapy. Lancet Oncol 15 : 669─671, 2014

21） McNeel DG, Smith HA, Eickhoff JC, et al : Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 61 : 1137─1147, 2012

22） Agata Y, Kawasaki A, Nishimura H, et al : Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8 : 765─772, 1996

23） Taube JM, Klein A, Brahmer JR, et al : Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20 : 5064─5074, 2014

24） Sfanos KS, Bruno TC, Meeker AK, et al : Human prostate-infiltrating CD8＋T lymphocytes are oligoclonal and PD-1＋. Prostate 69 : 1694─1703, 2009

25） Massari F, Ciccarese C, Calio A, et al : Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma : An Exploratory Analysis. Target Oncol 11 : 345─351, 2016

26） Gevensleben H, Dietrich D, Golletz C, et al : The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clin Cancer Res 22 : 1969─1977, 2016

27） Bishop JL, Sio A, Angeles A, et al : PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget 6 : 234─242, 2015